These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 31485275

  • 21. The product of duration and amount of proteinuria (proteinuria index) is a possible marker for glomerular and tubulointerstitial damage in IgA nephropathy.
    Eiro M, Katoh T, Kuriki M, Asano K, Watanabe K, Watanabe T.
    Nephron; 2002 Apr; 90(4):432-41. PubMed ID: 11961402
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of renal clinicopathological changes in IgA nephropathy by urinary podocytes excretion and podocalyxin expression.
    Jiang WL, Peng YM, Liu YH, Liu H, Chen GC, Xu XQ, Zhu XJ, Liu FY.
    Ren Fail; 2012 Apr; 34(7):821-6. PubMed ID: 22679920
    [Abstract] [Full Text] [Related]

  • 23. Urinary miRNA profile for the diagnosis of IgA nephropathy.
    Szeto CC, Wang G, Ng JK, Kwan BC, Mac-Moune Lai F, Chow KM, Luk CC, Lai KB, Li PK.
    BMC Nephrol; 2019 Mar 04; 20(1):77. PubMed ID: 30832601
    [Abstract] [Full Text] [Related]

  • 24. NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.
    Chen Y, Li H, Xiao C, Zeng X, Xiao X, Zhou Q, Xiao P.
    J Transl Med; 2018 Nov 19; 16(1):317. PubMed ID: 30453994
    [Abstract] [Full Text] [Related]

  • 25. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy.
    Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC.
    Dis Markers; 2011 Nov 19; 30(4):171-9. PubMed ID: 21694443
    [Abstract] [Full Text] [Related]

  • 26. Development and validation of a diagnostic nomogram to evaluate tubular atrophy/interstitial fibrosis of IgA nephropathy.
    Gan Y, Cai Y, Li J, Wu J, Zhang R, Han Q, Li W, Yang Q.
    Int J Med Sci; 2024 Nov 19; 21(4):674-680. PubMed ID: 38464822
    [Abstract] [Full Text] [Related]

  • 27. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.
    Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M, Toki A, Horikoshi S, Fujita T, Tomino Y.
    BMC Nephrol; 2011 Nov 23; 12():64. PubMed ID: 22111871
    [Abstract] [Full Text] [Related]

  • 28. Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy.
    Liu D, Liu Y, Chen G, He L, Tang C, Wang C, Yang D, Li H, Dong Z, Liu H.
    Am J Nephrol; 2017 Nov 23; 45(4):293-300. PubMed ID: 28237991
    [Abstract] [Full Text] [Related]

  • 29. Urinary Exosomes and Exosomal CCL2 mRNA as Biomarkers of Active Histologic Injury in IgA Nephropathy.
    Feng Y, Lv LL, Wu WJ, Li ZL, Chen J, Ni HF, Zhou LT, Tang TT, Wang FM, Wang B, Chen PS, Crowley SD, Liu BC.
    Am J Pathol; 2018 Nov 23; 188(11):2542-2552. PubMed ID: 30142333
    [Abstract] [Full Text] [Related]

  • 30. CD147 renal expression as a biomarker for progressive IgAN.
    Sun S, Zhao A, Li R, Du R, He L, Sun W, Wang H, Huang C.
    J Nephrol; 2015 Jun 23; 28(3):307-14. PubMed ID: 25510296
    [Abstract] [Full Text] [Related]

  • 31. High serum and urine neutrophil gelatinase-associated lipocalin levels are independent predictors of renal progression in patients with immunoglobulin A nephropathy.
    Rhee H, Shin N, Shin MJ, Yang BY, Kim IY, Song SH, Lee DW, Lee SB, Kwak IS, Seong EY.
    Korean J Intern Med; 2015 May 23; 30(3):354-61. PubMed ID: 25995666
    [Abstract] [Full Text] [Related]

  • 32. Urinary excretion of β2-microglobulin as a prognostic marker in immunoglobulin A nephropathy.
    Shin JR, Kim SM, Yoo JS, Park JY, Kim SK, Cho JH, Jeong KH, Lee TW, Ihm CG.
    Korean J Intern Med; 2014 May 23; 29(3):334-40. PubMed ID: 24851068
    [Abstract] [Full Text] [Related]

  • 33. Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.
    Tian S, Yang X, Luo J, Guo H.
    Int Immunopharmacol; 2020 Nov 23; 88():106896. PubMed ID: 33182045
    [Abstract] [Full Text] [Related]

  • 34. The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option.
    Tian J, Wang Y, Guo H, Li R.
    Exp Mol Pathol; 2015 Dec 23; 99(3):435-40. PubMed ID: 26297427
    [Abstract] [Full Text] [Related]

  • 35. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy.
    Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W.
    Clin Immunol; 2007 May 23; 123(2):227-34. PubMed ID: 17360238
    [Abstract] [Full Text] [Related]

  • 36. Urinary mi-106a for the diagnosis of IgA nephropathy: Liquid biopsy for kidney disease.
    Szeto CC, Ng JK, Fung WW, Chan GC, Luk CC, Lai KB, Wang G, Chow KM, Mac-Moune Lai F.
    Clin Chim Acta; 2022 May 01; 530():81-86. PubMed ID: 35278407
    [Abstract] [Full Text] [Related]

  • 37. Analysis of macrophages in urine sediments in children with IgA nephropathy.
    Maruhashi Y, Nakajima M, Akazawa H, Shimoyama H, Nishiguchi M, Yamoto Y, Kamitsuji H, Yoshioka A.
    Clin Nephrol; 2004 Nov 01; 62(5):336-43. PubMed ID: 15571177
    [Abstract] [Full Text] [Related]

  • 38. High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.
    Wang S, Dong L, Pei G, Jiang Z, Qin A, Tan J, Tang Y, Qin W.
    Front Immunol; 2021 Nov 01; 12():700224. PubMed ID: 34456912
    [Abstract] [Full Text] [Related]

  • 39. Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics.
    Wang D, Wu C, Chen S, Li Y, Wang L, Zhang Y, Li G.
    Front Immunol; 2023 Nov 01; 14():1117995. PubMed ID: 37020564
    [Abstract] [Full Text] [Related]

  • 40. Correlation analysis of cofilin-1 with renal prognosis in primary IgA nephropathy.
    Zhao RB, Xu YS, Li XH, Wei MJ, Deng Y, Peng X, Pan L.
    BMC Nephrol; 2024 Sep 03; 25(1):289. PubMed ID: 39227817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.